Poa pratensis pollen allergen (Kentucky bluegrass pollen allergen)

Poa pratensis pollen allergens are proteins that trigger allergic immune responses in sensitized individuals, and are not considered therapeutic targets in the traditional sense. They are allergens that elicit IgE-mediated immune responses, rather than receptors, enzymes, transporters, or other druggable molecular targets. The entry fundamentally contains a categorization error by implying it could be a drug target. Poa pratensis contains multiple allergenic molecules, including Poa p 1, Poa p 2, Poa p 5 (with isoforms Poa p 5a and Poa p 5b), and Poa p 10. The group V allergen (Poa p 5) shows significant cross-reactivity with other grass pollen allergens, particularly with homologous molecules from other Pooideae grasses. These proteins trigger IgE-mediated allergic responses in sensitized individuals, leading to hay fever and allergic asthma. While antihistamines, intranasal corticosteroids, and allergen immunotherapy (AIT) are used to manage allergic responses, these do not directly 'target' the allergen molecules in a pharmacological sense. Poa p 5 is a significant trigger of hay fever and allergic asthma, making it a marker for grass pollen sensitization testing.

Other names

Kentucky bluegrass pollen allergenMeadow grass allergenPoa p allergen

No direct pharmacological targeting mechanism for drugs interacting with the allergen itself; current treatments manage the allergic response or induce tolerance rather than directly targeting the allergen.